New beauty protocol addresses the hollowed cheeks and volume loss from GLP-1 weight-loss drugs.
A South Korean beauty firm has launched a fat-transfer protocol specifically designed to address the facial volume loss and hollowed appearance associated with GLP-1 weight-loss drugs—colloquially known as "Ozempic face." The procedure uses the patient's own adipose tissue to restore cheek and midface fullness.
This is not a new technique, but the targeting is. Fat transfer has long been a staple of facial rejuvenation, but framing it as a corrective treatment for GLP-1-induced atrophy opens a distinct revenue stream. The protocol sits at the intersection of two booming markets: GLP-1 adoption and aesthetic correction. For practices already offering body contouring to weight-loss patients, adding fat-transfer consultations to the post-loss protocol is a logical upsell.
Fat transfer targets the hollowed cheeks and midface volume loss from GLP-1 weight loss.
The economics differ from synthetic filler: fat requires harvesting, processing, and grafting—higher procedural complexity and time, but also higher margins and stronger patient retention (the procedure is perceived as more permanent). Practices should expect patient inquiries about this as GLP-1 penetration deepens, particularly among affluent demographics.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
